144
Views
9
CrossRef citations to date
0
Altmetric
Technology Evaluation

New solid-state chemistry technologies to bring better drugs to market: knowledge-based decision making

, , , , , , , & show all
Pages 145-154 | Published online: 16 Jan 2007

Bibliography

  • DIMASI JA, HANSEN RW, GRABOWSKI HG: The price of innovation: new estimates of drug development costs. J. Health Econ. (2003) 22(2):151-185.
  • HILFIKER R: Relevance of solid-state properties for pharmaceutical products. In: Polymorphism in the Pharmaceutical Industry. Hilfiker R (Ed.), Wiley-VCH, Weinheim, Germany and John Wiley, Chichester, UK (2006):1-19.
  • NEWMAN AW, BYRN SR: Solid-state analysis of the active pharmaceutical ingredient in drug products. Drug Discov. Today (2003) 8(19):898-905.
  • DATTA S, GRANT DNW: Crystal structures of drugs: advances in determination, prediction and engineering. Nat. Rev. Drug Discov. (2004) 3(1):42-57.
  • SHETH AR, GRANT DNW: Relationship between the structure and properties of pharmaceutical crystals. KONA (2005) 23:36-48.
  • BYRN SR, PFEIFFER RR, STOWELL JG: Solid-state chemistry of drugs. (2nd edn.) (1999):574.
  • CHEMBURKAR SR, BAUER J, DEMING K et al.: Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Pro. Res. Devel. (2000) 4(5):413-417.
  • BAUER J, SPANTON S, HENRY R et al.: Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. (2001) 18(6):859-866.
  • DU Q, PING QN: Investigation of buspirone hydrochloride polymorphs. Zhongguo Yaoke Daxue Xuebao (2000) 31(2):102-104.
  • SHEIKHZADEH M, ROHANI S, JUTAN A, MANIFAR T, MURTHY K, HORNE S: Solid-state characterization of buspirone hydrochloride polymorphs. Pharm. Res. (2006) 23(5):1043-1050.
  • CHILDS SL, CHYALL LJ, DUNLAP JT, COATES DA, STAHLY BC, STAHLY GP: A metastable polymorph of metformin hydrochloride: isolation and characterization using capillary crystallisation and thermal microscopy techniques. Crystal Growth Des. (2004) 4(3):441-449.
  • PETERSON ML, MORISSETTE SL, MCNULTY C et al.: Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. J. Am. Chem. Soc. (2002) 124(37):10958-10959.
  • IVANISEVIC I, BUGAY DE, BATES S: On pattern matching of X-ray powder diffraction data. J. Phys. Chem. B Condens. Matter Mater. Surf. Interfaces Biophys. (2005) 109(16):7781-7787.
  • CHEN X, BATES S, MORRIS KR: Quantifying amorphous content of lactose using parallel beam X-ray powder diffraction and whole pattern fitting. J. Pharm. Biomed. Anal. (2001) 26(1):63-72.
  • DOCHERTY R, CLYDESDALE G, ROBERTS KJ, BENNEMA P: Application of Bravais-Friedel-Donnay-Harker, attachment energy and ising-models to predicting and understanding the morphology of molecular-crystals. J. Phys. D-Appl. Phys. (1991) 24(2):89-99.
  • DONNAY JD, HARKER D: A new law of crystal morphology extending the law of bravais. Am. Mineral. (1937) 22:446-467.
  • FLORENCE AJ, BAUMGARTNER B, WESTON C et al.: Indexing powder patterns in physical form screening: instrumentation and data quality. J. Pharm. Sci. (2003) 92(9):1930-1938.
  • SPERANDEO NR, KARLSSON A, CUFFINI S, PAGOLA S, STEPHENS PW: The crystal structure and physicochemical characteristics of 2-hydroxy-N-[3(5)-pyrazolyl]-1,4-naphthoquinone-4-imine, a new antitrypanosomal compound. AAPS PharmSciTech (2005) 6(4):E655-E663.
  • STAHLY GP, BATES S, ANDRES MC, COWANS BA: Discovery of a new polymorph of dehydroepiandrosterone (Prasterone) and solution of its crystal structure from X-ray powder diffraction data. Crystal Growth Des. (2006) 6(4):925-932.
  • BURGER A, RAMBERGER R: On the polymorphism of pharmaceuticals and other molecular crystals. I. Theory and thermodynamic rules. Mikrochim. Acta (1979) 2:259-271.
  • CHILMONCZYK Z, LES A, WOZNIAKOWSKA A, CYBULSKI J, KOZIOL AE, GDANIEC M: Buspirone analogues as ligands of the 5-HT1A receptor. 1. The molecular structure of buspirone and its two analogues. J. Med Chem. (1995) 38(10):1701-1710.
  • MCNAMARA P, CHILDS S, GIODANO J et al.: Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm. Res. (2006) 23(8):1888-1897.
  • SHETH AR, BATES S, MULLER FX, GRANT DJ: Local structure in amorphous phases of piroxicam from powder X-ray Diffractometry Crystal Growth Des. (2005) 5(2):571-578.
  • BAERLOCHER C, MCCUSKER LB: Structure determination from powder diffraction data. Zeitschrift für Kristallographie (2004) 219(12):782-782.
  • BERGMANN J, LE BAIL A, SHIRLEY R, ZLOKAZOV V: Renewed interest in powder diffraction data indexing. Zeitschrift für Kristallographie (2004) 219(12):783-790.
  • SHANKLAND K, MARKVARDSEN A, DAVID WI: Powder diffraction based structural studies of pharmaceuticals. Zeitschrift für Kristallographie (2004) 219(12):857-865.
  • CHILDS SL, CHYALL LJ, DUNLAP JT, SMOLENSKAYA VN, STAHLY BC, STAHLY GP: Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J. Am. Chem. Soc. (2004) 126(41):13335-13342.
  • TRASK AV, MOTHERWELL WD, JONES W: Physical stability enhancement of theophylline via cocrystallization. Int. J. Pharm. (2006) 320(1):114-123.
  • LEE J: Drug nano- and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci. (2003) 92(10):2057-2068.

Patents

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.